Quantitative DCEMRI of Prostate Cancer Correlation with Gold Standards

前列腺癌的定量 DCEMRI 与金标准的相关性

• 批准号: 8422144
• 负责人: Gregory S. Karczmar
• 金额: $ 47.17万
• 依托单位: UNIVERSITY OF CHICAGO
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-08-01 至 2018-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8422144
• 关键词: Address; Arteries; Biological; Blood; Blood specimen; Bolus Infusion; Calibration; Cancer Patient; Cardiac Output; Chicago; Clinical; Collaborations; Communities; Contrast Media; Data; Data Analyses; Data Set; Databases; Development; Diagnosis; Diffusion weighted imaging; Discrimination; Dose; Drug Kinetics; Early Diagnosis; Error Sources; Gleason Grade for Prostate Cancer; Goals; Gold; Histology; Image; In Vitro; Injection of therapeutic agent; Institution; Letters; Magnetic Resonance Imaging; Malignant Neoplasms; Malignant neoplasm of prostate; Measurement; Measures; Medical; Methods; Morphologic artifacts; Outcome; Patients; Phase; Physiological; Procedures; Protocols documentation; Research; Research Personnel; Resolution; Resources; Scanning; Sensitivity and Specificity; Source; Staging; System; Testing; Time; Tissues; Translations; Universities; anticancer research; base; clinical application; clinical practice; data acquisition; design; diagnostic accuracy; improved; in vivo; innovation; novel strategies; public health relevance; screening; tool

DESCRIPTION (provided by applicant): Dynamic contrast enhanced MRI (DCEMRI) has potential to provide critical information to guide therapy and improve outcomes for prostate cancer (PCa) patients. However, sensitivity and specificity are not yet adequate for routine clinical use. DCEMRI has not been demonstrated to reliably differentiate between high Gleason score cancers and low Gleason score cancers. It is not known whether poor diagnostic accuracy is due to measurement error or to underlying biological variability. While a wide range of methods have been proposed to improve DCEMRI, there have been few attempts to validate these methods against gold standards, to determine whether contrast dynamics are accurately measured. To address these problems, we propose to a) Develop innovative quantitative approaches to DCEMRI that have the potential to increase diagnostic accuracy. b) Test DCEMRI against 'gold standards', to determine accuracy and variability, and guide the development of improvements that reduce error. c) Determine whether quantitative DCEMRI can improve discrimination of high Gleason grade from low Gleason grade cancers. We propose the following specific aims: 1. Quantitatively measure contrast media concentration, arterial input function, and physiological parameters (e.g. Ktrans) using innovative approaches developed at the University of Chicago. 2. Validate measurements of contrast media concentration, the arterial input function, Ktrans, and ve, using gold standard measurements, including dynamic contrast enhanced CT, direct measurements of blood concentration of contrast media, and measurements of cardiac output. 3. Evaluate variability of parameters extracted from DCEMRI data. Identify sources of variability - based on the gold-standard measurements and modify procedures to minimize variability. 4. Correlate Gleason grade with quantitative DCEMRI results. 5. Establish a curated imaging database consisting of registered multiparametric in vivo MRI, gold standard measurements, and in vitro histological images. This includes data from DCEMRI, diffusion- weighted-imaging (DWI), CT, calibration scans, parameters from quantitative analysis, and histology. This will provide researchers at other institutions with a valuable database that can be used to test quantitative analysis methods. The proposed research will provide validated DCEMRI methods that improve diagnosis and staging of Pca, and will also impact other applications of DCEMRI. The research will provide important resources for the prostate cancer research community, as evidenced by letters of support by internationally recognized experts. In addition, the collaboration with Philips Medical Systems (see letter of support) will insure rapid translation of results to clinical practice.

描述（由申请人提供）：动态对比增强的MRI（DCEMRI）具有提供关键信息来指导治疗并改善前列腺癌（PCA）患者的预后。但是，灵敏度和特异性尚不适合常规临床使用。尚未证明DCEMRI可以可靠地区分高格里森评分癌和低格里森评分癌。尚不清楚诊断准确性差是由于测量误差还是潜在的生物学变异性。尽管已经提出了广泛的方法来改善DCEMRI，但很少有尝试根据黄金标准验证这些方法，以确定是否准确测量了对比度动力学。为了解决这些问题，我们建议a）为DCEMRI开发具有提高诊断准确性的DCEMRI的创新定量方法。 b）针对“黄金标准”测试dcemri，以确定准确性和可变性，并指导发展误差的改进的发展。 c）确定定量dcemri是否可以改善对低格里森级癌症对高gleason等级的歧视。我们提出以下具体目的：1。使用芝加哥大学开发的创新方法来定量衡量对比度培养基的浓度，动脉输入功能和生理参数（例如KTRAN）。 2。使用黄金标准测量值（包括动态对比度增强的CT，直接测量对比度介质的血液浓度的直接测量以及心脏输出的测量）来验证对比度介质浓度，动脉输入功能，KTRAN和VE。 3。评估从DCEMRI数据中提取的参数的可变性。根据金标准测量值并修改程序以最大程度地减少变异性，确定可变性的来源。 4。将格里森等级与定量dcemri结果相关。 5。建立一个由注册的多参数MRI，黄金标准测量和体外组织学图像组成的策划成像数据库。这包括来自DCEMRI的数据，扩散加权成像（DWI），CT，校准扫描，定量分析和组织学的参数。这将为其他机构的研究人员提供一个有价值的数据库，可用于测试定量分析方法。 拟议的研究将提供验证的DCEMRI方法，以改善PCA的诊断和分期，并将影响DCEMRI的其他应用。这项研究将为前列腺癌研究界提供重要的资源，这是由国际认可的专家提供的支持信所证明的。此外，与飞利浦医疗系统的合作（请参阅支持信）将确保将结果快速转化为临床实践。